First Time Loading...

Akebia Therapeutics Inc
NASDAQ:AKBA

Watchlist Manager
Akebia Therapeutics Inc Logo
Akebia Therapeutics Inc
NASDAQ:AKBA
Watchlist
Price: 1.455 USD -2.35% Market Closed
Updated: May 7, 2024

Akebia Therapeutics Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Akebia Therapeutics Inc
Cash from Operating Activities Peer Comparison

Comparables:
ABBV
GILD
AMGN
VRTX
REGN

Competitive Cash from Operating Activities Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
Akebia Therapeutics Inc
NASDAQ:AKBA
Cash from Operating Activities
-$23.4m
CAGR 3-Years
40%
CAGR 5-Years
25%
CAGR 10-Years
-8%
Abbvie Inc
NYSE:ABBV
Cash from Operating Activities
$22.8B
CAGR 3-Years
9%
CAGR 5-Years
11%
CAGR 10-Years
14%
Gilead Sciences Inc
NASDAQ:GILD
Cash from Operating Activities
$8B
CAGR 3-Years
-5%
CAGR 5-Years
1%
CAGR 10-Years
7%
Amgen Inc
NASDAQ:AMGN
Cash from Operating Activities
$8.1B
CAGR 3-Years
-8%
CAGR 5-Years
-5%
CAGR 10-Years
2%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Cash from Operating Activities
$3.5B
CAGR 3-Years
3%
CAGR 5-Years
23%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Cash from Operating Activities
$4.7B
CAGR 3-Years
22%
CAGR 5-Years
14%
CAGR 10-Years
24%

See Also

What is Akebia Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
-23.4m USD

Based on the financial report for Dec 31, 2023, Akebia Therapeutics Inc's Cash from Operating Activities amounts to -23.4m USD.

What is Akebia Therapeutics Inc's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-8%

Over the last year, the Cash from Operating Activities growth was 68%. The average annual Cash from Operating Activities growth rates for Akebia Therapeutics Inc have been 40% over the past three years , 25% over the past five years , and -8% over the past ten years .